KCNH2 and head and neck squamous cell carcinoma: In good agreement to our previous observations using the anti-HERG1 pan (CT) antibody11, using the same cohort of HNSCC patients we found that the expression of HERG1A isoform (specifically obtained with an anti-HERG1A (NT) antibody) also increased during tumour progression and associated significantly with lymph node metastasis (N1-3 versus N0, P = 0.018, Supplementary Table S2), advanced disease stages (III and IV versus I-II, P < 0.001), with tumour recurrence (P = 0.028) and distant metastasis (P = 0.038).